BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetites. A new ...
Hosted on MSN
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
BioAge Labs is having its initial public offering today. The drug developer’s signature product, Azelaprag, isn’t yet on sale, but it is undergoing clinical trials in hopes it will one day be. What ...
Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...
RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback